HKG:2591

3 stories mentioning HKG:2591Updated 2d ago

Every FINWIRES story that references HKG:2591, newest first.

Innogen Pharma's Efsubaglutide Manufacturing Sites Receive Brazil GMP Certification

Guangzhou Innogen Pharmaceutical (HKG:2591) said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice (GMP) certification from Brazil's health regulator, ANVISA.The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.

HKG:2591

Asia8d ago

Innogen Pharma Doses First Patient in Phase 1b Trial of Obesity Drug

Guangzhou Innogen Pharmaceutical (HKG:2591) has enrolled and dosed the first patient in the Phase 1b clinical trial of Efsubaglutide Alfa for the treatment of adolescent obesity, according to a Tuesday Hong Kong bourse filing.The company said that no safety concerns or adverse reactions were observed during the post-dosing observation period.Shares of the pharma company were up more than 2% in Wednesday morning trade.

HKG:2591

Asia45d ago

Innogen Pharma Gets Clinical Trial Nod for Obesity Drug in China

Guangzhou Innogen Pharmaceutical (HKG:2591) obtained approval to conduct phase Ib clinical trials for Efsubaglutide Alfa from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The drug is being tested for the treatment of obesity in adolescents.The company expects to begin the trial in July and enroll around 36 participants.

HKG:2591

Track with the FINWIRES app suite

FolioX

Track HKG:2591 in your portfolio

WheelAI

Analyze HKG:2591 options with the wheel strategy

StockInsider

See market sentiment on HKG:2591